CareDx Business Summary

CareDx, Inc. (CDNA) is a precision medicine leader specializing in high-value diagnostic solutions for transplant patients, generating revenue through a diversified model of testing services, product sales, and digital health subscriptions. The company operates three primary business segments: Testing Services, which provides non-invasive molecular monitoring such as AlloSure (dd-cfDNA) and AlloMap (gene expression profiling) for organ rejection; Products, which includes AlloSeq and other laboratory-developed kits for HLA typing; and Patient and Digital Solutions, offering workflow software and medication adherence tools like MediGO and MedActionPlan. CareDx maintains a dominant market position as a specialized end-to-end transplant care provider, competing directly against diversified genomic giants and niche players such as Natera, Eurofins Scientific (Transplant Genomics), Veracyte, and Qiagen NV. Originally founded in 1998 as Hippocratic Engineering by Dr. John Scandling and Dr. Minnie Sarwal, the company is currently led by President and CEO John W. Hanna, who previously served as a senior executive at Veracyte. The leadership team includes Chief Technology Officer Kashif Rathore, Chief Financial Officer Nathan Smith, and Chief Operating Officer Keith Kennedy, all of whom bring extensive experience in molecular diagnostics and healthcare operations. The company’s strategic direction is overseen by a board chaired by Michael Goldberg and featuring notable members such as Suresh Gunasekaran, CEO of UCSF Health. CareDx is backed by major institutional investors including BlackRock, Vanguard, and ARK Investment Management, reflecting its status as a core holding in the genomics and precision medicine sectors.